Immunohistochemical detection and localization of somatostatin receptor subtypes in prostate tissue from patients with bladder outlet obstruction.
Immunohistochemical detection and localization of somatostatin receptor subtypes in prostate tissue from patients with bladder outlet obstruction.
复制标题
膀胱出口梗阻患者前列腺组织中生长抑素受体亚型的免疫组织化学检测和定位。
DOI：
10.3233/clo-2008-0433
复制
发表时间：
2008
期刊：
影响因子：
--
通讯作者：
Bono AV
中科院分区：
文献类型：
--
作者：
Montironi R;Cheng L;Mazzucchelli R;Morichetti D;Stramazzotti D;Santinelli A;Moroncini G;Galosi AB;Muzzonigro G;Comeri G;Lovisolo J;Cosciani-Cunico S;Bono AV
研究背景和目的：很少有研究报道了正常前列腺和前列腺肿瘤中五种生长激素抑制素受体（SSTR）亚型的细胞分布信息，其中应用了原位杂交组织化学、放射自显影和最近的免疫组织化学等技术。本研究的目的是用化学方法检测这5种亚型在正常前列腺组织中的分布和定位。 材质：该研究在14例来自膀胱出口梗阻患者的腺瘤切除术标本的正常前列腺组织中进行。用免疫组织化学方法研究了5种生长抑素受体亚型在脑组织中的分布和定位。初步研究了5种受体亚型抗体的特异性。 结果：近90%的分泌细胞胞浆呈弱阳性，阳性率为86.3%（SSTR 4）~ 89.9%（SSTR 5）。在一小部分细胞中观察到强免疫反应性，范围为0.8%（SSTR 3）至3.2%（SSTR 1）。对于亚型1和3的基底细胞的最大比例表现出中等强度（42.5和41.4%，分别），强免疫反应性被观察到仅在18.1和15.8%的细胞，分别。对于亚型2、4和5，大多数细胞显示出弱强度（分别为72.3%、65.7%和65.1%）。亚型1在60%的平滑肌细胞胞浆中呈强免疫反应性。对于亚型2、3和4，最大比例的细胞显示出弱强度（分别为63.4、89.8和81.7%）。对于亚型5，大多数细胞（59.8%）为阴性。亚型1在98.6%的内皮细胞胞浆中呈强阳性反应。对于亚型3和4，最大比例的细胞显示出弱强度（分别为73.5%和56.4%）。对于亚型2和5，大多数细胞为阴性（分别为59.1%和50.7%）。 结论：我们对SSTR的免疫组化研究扩展了我们对这些亚型在前列腺各种组织成分中分布的了解。这样的信息可以证明在开发用于预防和治疗良性前列腺增生，特别是前列腺的癌前病变和肿瘤病变的进一步非手术策略中是有用的。
Background and Aim of the Study: Scant information on the cellular distribution of the five somatostatin receptor (SSTR) subtypes in the normal prostate and in neoplasms of the prostate has been reported in very few studies in which techniques, such as in situ hybridization histochemistry, autoradiography, and more recently immunohistochemistry, have been applied. The aim of the study was to examine immunohistochemically the distribution and localization of these 5 subtypes in the various tissue components in normal prostate. Materials: The study was conducted in 14 surgical specimens of normal prostate tissue from adenomectomy specimens from patients with bladder outlet obstruction. The distribution and localization of the 5 somatostatin receptor (SSTR) subtypes was investigated with an immunohistochemical technique. Specificity of the antibodies against the 5 receptor subtypes was preliminarily investigated. Results: Close to 90% of secretory cells showed a weak positivity in the cytoplasm, the proportion ranging from 86.3% (SSTR4) to 89.9% (SSTR5). Strong immunoreactivity was seen in a small proportion of cells, ranging from 0.8% (SSTR3) to 3.2% (SSTR1). For the subtypes 1 and 3 the greatest proportion of basal cells showed a moderate intensity (42.5 and 41.4%, respectively), strong immunoreactivity being observed only in 18.1 and 15.8% of cells, respectively. For the subtypes 2, 4 and 5, the majority of cells showed a weak intensity (72.3, 65.7 and 65.1%, respectively). Subtype 1 showed a strong immunoreactivity in the cytoplasm in 60% of the smooth muscle cells. With subtypes 2, 3 and 4 the greatest proportion of cells showed a weak intensity (63.4, 89.8 and 81.7%, respectively). With the subtype 5 the majority of cells (59.8%) were negative. Subtype 1 showed a strong immunoreactivity in the cytoplasm in 98.6% of the endothelial cells. With subtypes 3 and 4 the greatest proportion of cells showed a weak intensity (73.5 and 56.4%, respectively). With the subtype 2 and 5 the majority of cells were negative (59.1 and 50.7%, respectively). Conclusions: Our immunohistochemical study on the SSTRs expands our knowledge in the distribution of these subtypes in the various tissue components in the prostate. Such an information may prove useful in developing further non-surgical strategies for the prevention and treatment of benign prostatic hyperplasia and, in particular, of preneoplastic and neoplastic lesions of the prostate.